<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354884</url>
  </required_header>
  <id_info>
    <org_study_id>INT 150/17</org_study_id>
    <nct_id>NCT03354884</nct_id>
  </id_info>
  <brief_title>caBozantinib in cOllectiNg ductS Renal Cell cArcInoma</brief_title>
  <acronym>BONSAI</acronym>
  <official_title>caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate&#xD;
      activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic&#xD;
      Collecting Duct Renal Cell Carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, phase II trial (monocentric)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>30 Month</time_frame>
    <description>To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free Survival (PFS)</measure>
    <time_frame>30 Month</time_frame>
    <description>To evaluate activity of Cabozantinib in terms of PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>30 Month</time_frame>
    <description>To evaluate activity of Cabozantinib in terms of OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability (Adverse Events)</measure>
    <time_frame>30 Month</time_frame>
    <description>To evaluate tolerability of Cabozantinibv during the treatment in particular the Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Collecting Duct Carcinoma (Kidney)</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive open label Cabozantinib 60 mg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabozantinib</intervention_name>
    <description>cabozantinib 60 mg orally once daily</description>
    <arm_group_label>Cabozantinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written Informed Consent Form&#xD;
&#xD;
          2. Unresectable, advanced or metastatic collecting ducts carcinoma untreated with any&#xD;
             systemic agent for advanced disease&#xD;
&#xD;
          3. Measurable disease as defined by RECIST v1.1 criteria&#xD;
&#xD;
          4. Age ≥18 years&#xD;
&#xD;
          5. ECOG Performance Status 0-1&#xD;
&#xD;
          6. Any of the following laboratory test findings:&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL (5.6 mmol/L)&#xD;
&#xD;
               -  WBC &gt; 2,000/mm3&#xD;
&#xD;
               -  Neutrophils &gt; 1,500/mm3&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
               -  AST or ALT &lt; 3 x ULN (&lt; 5 x ULN if liver metastases are present)&#xD;
&#xD;
               -  Total Bilirubin &lt; 1.5 x ULN (except subjects with Gilbert Syndrome, who can have&#xD;
                  total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x upper limit of normal (ULN) or creatinine clearance ≥ 40&#xD;
                  mL/min (measured or calculated by Cockroft-Gault formula)&#xD;
&#xD;
               -  Lipase &lt; 2.0 x the upper limit of normal and no radiologic or clinical evidence&#xD;
                  of pancreatitis&#xD;
&#xD;
               -  PT-INR/PTT ≤ 1.5 x upper limit of normal [Patients who are being therapeutically&#xD;
                  anticoagulated with an agent such as coumadin or heparin will be allowed to&#xD;
                  participate provided that no prior evidence of underlying abnormality in these&#xD;
                  parameters exists.] For patients on warfarin, close monitoring of at least weekly&#xD;
                  evaluations will be performed, until INR is stable based on a measurement at&#xD;
                  pre-dose, as defined by the local standard of care&#xD;
&#xD;
          7. Availability of a representative FFPE tumor specimen collected within 24 months of&#xD;
             starting first-line cabozantinib that enables the definitive diagnosis of CDC (the&#xD;
             archival specimen must contain adequate viable tumor tissue to enable candidate&#xD;
             biomarkers status; the specimen may consist of a tissue block or at least 15 unstained&#xD;
             serial sections; for core needle biopsy specimens, at least two cores should be&#xD;
             available for evaluation)&#xD;
&#xD;
          8. Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception (eg, barrier methods, including male condom, female&#xD;
             condom, or diaphragm with spermicidal gel) during the study and for 4 months after the&#xD;
             last dose of study treatment&#xD;
&#xD;
          9. Female subjects of childbearing potential must not be pregnant at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous therapy for advanced disease; any medical adjuvant treatment must have been&#xD;
             stopped at least six months before entry into the study&#xD;
&#xD;
          2. History of any one or more of the following cardiovascular conditions within the past&#xD;
             6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina,&#xD;
             coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class&#xD;
             III or IV congestive heart failure, as defined by the New York Heart Association&#xD;
             (NYHA)&#xD;
&#xD;
          3. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg&#xD;
             or diastolic blood pressure (DBP) of ≥ 90mmHg].&#xD;
&#xD;
          4. History of cerebrovascular accidents, including transient ischemic attack (TIA),&#xD;
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.&#xD;
             Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating&#xD;
             agents for at least 6 weeks are eligible&#xD;
&#xD;
          5. Major surgery or trauma within 28 days before to study entry; the such as catheter&#xD;
             placement not considered to be major surgery).&#xD;
&#xD;
          6. Known brain metastases or cranial epidural disease unless adequately treated with&#xD;
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months&#xD;
             before randomization.&#xD;
&#xD;
          7. Evidence of active bleeding or bleeding diathesis and/or clinically-significant GI&#xD;
             bleeding within 6 months before the first dose of study treatment; 3 months for&#xD;
             pulmonary hemorrhage and patients with tumor invading or encasing any major blood&#xD;
             vessels.&#xD;
&#xD;
          8. Patients with GI disorders associated with a high risk of perforation or fistula&#xD;
             formation.&#xD;
&#xD;
          9. Subjects with clinically relevant ongoing complications from prior radiation therapy.&#xD;
&#xD;
         10. Any serious and/or unstable pre-existing medical, psychiatric, or other conditions&#xD;
             that could interfere with subject's safety, provision of informed consent, or&#xD;
             compliance to study procedures.&#xD;
&#xD;
         11. Previous or ongoing treatment (except for adjuvant therapies) with any of the&#xD;
             following anti-cancer therapies: chemotherapy, immunotherapy, target therapies,&#xD;
             investigational therapy or hormonal therapy within 14 days or five half-lives of a&#xD;
             drug (whichever is longer) prior to the first dose of Cabozantinib&#xD;
&#xD;
         12. Inability to swallow tablets or capsules.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Procopio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori - Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Giuseppe Procopio</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Abbas M, Steffens S, Bellut M, Eggers H, Großhennig A, Becker JU, Wegener G, Schrader AJ, Grünwald V, Ivanyi P. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med Oncol. 2016 Jul;33(7):80. doi: 10.1007/s12032-016-0794-0. Epub 2016 Jun 17.</citation>
    <PMID>27317388</PMID>
  </reference>
  <reference>
    <citation>Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov;25(11):2178-2184. doi: 10.1093/annonc/mdu445. Epub 2014 Sep 5.</citation>
    <PMID>25193987</PMID>
  </reference>
  <reference>
    <citation>Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.</citation>
    <PMID>26406150</PMID>
  </reference>
  <reference>
    <citation>Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.</citation>
    <PMID>27279544</PMID>
  </reference>
  <reference>
    <citation>Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14. Erratum in: J Clin Oncol. 2017 Nov 10;35(32):3736. J Clin Oncol. 2018 Feb 10;36(5):521.</citation>
    <PMID>28199818</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012 Mar 22;12(4):253-68. doi: 10.1038/nri3175. Review.</citation>
    <PMID>22437938</PMID>
  </reference>
  <reference>
    <citation>Geissler K, Fornara P, Lautenschläger C, Holzhausen HJ, Seliger B, Riemann D. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology. 2015 Feb 3;4(1):e985082. eCollection 2015 Jan.</citation>
    <PMID>25949868</PMID>
  </reference>
  <reference>
    <citation>Iacovelli R, Nolè F, Verri E, Renne G, Paglino C, Santoni M, Cossu Rocca M, Giglione P, Aurilio G, Cullurà D, Cascinu S, Porta C. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Target Oncol. 2016 Apr;11(2):143-8. doi: 10.1007/s11523-015-0392-7. Review.</citation>
    <PMID>26429561</PMID>
  </reference>
  <reference>
    <citation>Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol. 2015 Oct 15;10:189. doi: 10.1186/s13000-015-0414-x.</citation>
    <PMID>26470780</PMID>
  </reference>
  <reference>
    <citation>Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, Arakelyan N, Culine S; GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007 May;177(5):1698-702.</citation>
    <PMID>17437788</PMID>
  </reference>
  <reference>
    <citation>Pécuchet N, Bigot F, Gachet J, Massard C, Albiges L, Teghom C, Allory Y, Méjean A, Escudier B, Oudard S. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann Oncol. 2013 Dec;24(12):2963-7. doi: 10.1093/annonc/mdt423. Epub 2013 Nov 4.</citation>
    <PMID>24190963</PMID>
  </reference>
  <reference>
    <citation>Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.</citation>
    <PMID>25428503</PMID>
  </reference>
  <reference>
    <citation>Procopio G, Testa I, Iacovelli R, Grassi P, Verzoni E, Garanzini E, Colecchia M, Torelli T, De Braud F. Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res. 2014 Feb;34(2):1027-30.</citation>
    <PMID>24511050</PMID>
  </reference>
  <reference>
    <citation>Procopio G, Verzoni E, Iacovelli R, Colecchia M, Torelli T, Mariani L. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol. 2012 Jun;16(3):464-7. doi: 10.1007/s10157-012-0589-3. Epub 2012 Jan 26.</citation>
    <PMID>22278601</PMID>
  </reference>
  <reference>
    <citation>Selli C, Amorosi A, Vona G, Sestini R, Travaglini F, Bartoletti R, Orlando C. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J Urol. 1997 Jul;158(1):245-7.</citation>
    <PMID>9186368</PMID>
  </reference>
  <reference>
    <citation>Shin SJ, Jeon YK, Kim PJ, Cho YM, Koh J, Chung DH, Go H. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. Ann Surg Oncol. 2016 Feb;23(2):694-702.</citation>
    <PMID>26464193</PMID>
  </reference>
  <reference>
    <citation>Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.</citation>
    <PMID>24714771</PMID>
  </reference>
  <reference>
    <citation>Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012 Aug;18(8):1254-61. doi: 10.1038/nm.2883. Epub 2012 Jul 29.</citation>
    <PMID>22842478</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

